logo
Are July 4th Fireworks Bad For the Environment?

Are July 4th Fireworks Bad For the Environment?

Fireworks are equal parts lovely and ugly—lovely because, well, they're fireworks, and who doesn't enjoy a good pyrotechnic sky show? The ugly part comes mostly after, in the haze of toxic gases and particles the blasts produce, along with the rain of paper, cardboard, and metal debris, and the lingering trauma to pets and wildlife, who take a lot less pleasure from the bangs and flashes than we do.
According to estimates by the American Pyrotechnics Association (APA), the average July 4th in the U.S. will see about 14,000 public fireworks displays. In 2021, the last year for which the APA provides figures, Americans bought and launched more than 428 million lbs. of fireworks. That's an awful lot of ordnance—and it can produce an awful lot of problems.
One of the biggest environmental dangers of fireworks displays is the dispersal of fine particles of sulfur dioxide, nitrogen oxide, and more, measuring just 2.5 microns—or 2.5 millionths of a meter. These so-called PM2.5 particles can become deeply embedded in the lungs and even enter the bloodstream, contributing to decreased lung function, increased respiratory distress, aggravated asthma and COPD, irregular heartbeat, heart attacks, and premature death in people with preexisting heart or lung disease, according to the Environmental Protection Agency (EPA). One 2015 study in the journal Atmospheric Environment found that levels of PM2.5 particles rose 42% at 315 firework sites surveyed nationwide during July 4th celebrations. The increases peaked between the hours of 9:00 and 10:00 p.m. and didn't dissipate until noon on July 5. Spikes in some lung conditions may occur from a single fireworks show.
"Fireworks massively reduce air quality with their explosions of particulate matter," says Bill Bateman, associate professor in the school of molecular and life sciences at Australia's Curtin University. "This can have a pretty immediate effect on our breathing and our health. In many places around the world there are reported peaks in respiratory problems after fireworks."
'What level of exposure you get depends on your activity levels—for instance, whether you're outdoors—and, if you're indoors, how leaky your house is,' said Jun Wu, a professor of environmental and occupational health at the University of California, Irvine's program in public health, in a 2024 conversation with TIME. 'If you have to go outside, wearing a [N95] mask would be good.'
Particles aren't all fireworks produce. According to a 2024 study in Applied Geochemistry, they also release, carbon dioxide, and carbon monoxide—which can cause lung damage—along with several metals, including aluminum, manganese, and cadmium. Some illegal fireworks may even contain lead, warns the American Lung Association (ALA). It is not generally possible to determine if fireworks contain lead since it won't be listed on the ingredients. The Consumer Products Safety Commission recommends buying only known, reputable brands.
Airborne contaminants will ultimately settle out—but that can be a problem because they may wind up in water and soil and on plants. Perchlorates, a common ingredient in fireworks, flares, fertilizer, and solid rocket fuel, can pollute lakes, rivers, and reservoirs, endangering wildlife and entering the drinking water supply. In humans, perchlorates affect the function of the thyroid gland, which can alter metabolism. In infants and babies still in the womb, perchlorates may interfere with normal growth and central nervous system development. Soil, too, collects more than trace amounts of perchlorates, along with metals. By themselves, the perchlorates found in fireworks may not be enough to cause harm, but they add to the overall load of the chemical in the environment, which can ultimately be dangerous.
Contamination that winds up in water and soil tends to linger there—perhaps longer than expected. From 1999 to 2009, fireworks displays were set off on Independence Days at Mt. Rushmore in South Dakota. From 2011 to 2015 researchers from the United States Geological Survey (USGS) returned and sampled water from 106 sites and soil from 11 sites in that vicinity. All of them showed perchlorate contamination and fireworks debris—especially on the northeast side of the park, where the pyrotechnics went off.
'The lack of alternative perchlorate sources in the area, such as a military site or agricultural land with applied fertilizers, and the presence of firework debris, suggest that past fireworks are the perchlorate source,' said one USGS scientist in a statement.
Animals suffer too, both from the same pollutants that threaten humans and from the noise and light of fireworks displays. One 2023 paper in Pacific Conservation Biology reported that nearly 75% of companion animals studied—from horses to dogs to smaller mammals—showed fear responses to fireworks. Some horses broke paddock fences and sustained injury trying to escape the flashes and bangs. Fireworks displays can interfere with the breeding season of birds, with one study the 2023 paper cites showing that fireworks festivals in Valencia, Spain, in April and May of 2015 reduced the breeding success of house sparrows. When the pyrotechnics were canceled in 2020 due to the COVID-19 pandemic, the sparrow populations bounced back. Independence Day celebrations in California similarly diminished populations of Brandt's Cormorants.
"Disturbing roosting migratory birds at night can result in mass deaths," says Bateman. "Disturbing breeding birds can result in colony collapses. Seals and sea lions leave [affected] areas and expend energy swimming away during fireworks."
And then there's the problem of litter. Every exploding firework rocket will eventually tumble and flutter down to the ground in a cloud of debris. "There are local peaks in microplastics and other plastic waste after fireworks," says Bateman. "Once in the environment they are there for good effectively."
There are alternatives to fireworks. Both drones and laser shows can produce visual spectacles that have no environmental footprint apart from the energy used to operate them, and health and environmental groups are increasingly calling for towns, cities, and individuals to make the switch. The Fourth of July celebrates the founding of the nation. What better way to honor that nation than to keep it peaceful and clean?
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Texas woman sues Marine, claiming he spiked her drink with abortion pills
Texas woman sues Marine, claiming he spiked her drink with abortion pills

NBC News

timean hour ago

  • NBC News

Texas woman sues Marine, claiming he spiked her drink with abortion pills

A Texas woman is suing a U.S. Marine, alleging he spiked her drink with nearly a dozen abortion pills, killing their unborn child, after she rebuffed his repeated requests to 'get rid of it,' according to a wrongful death lawsuit filed in federal court Monday. Liana Davis alleges Christopher Cooprider secretly dissolved at least 10 abortion pills into a cup of hot chocolate that he prepared for her April 5 and then left the house and stopped responding as she profusely bled, the suit says. Cooprider, 34, declined to comment Monday. The lawsuit, filed in the U.S. District Court for the Southern District of Texas, contains several purported text messages the pair exchanged for weeks, beginning Jan. 31, when Davis asked Cooprider for his input in case she is confirmed to be pregnant. Cooprider said he 'would like to get rid of it,' the texts show, saying the two were 'not in love' or together and that it would be 'messed up to bring a child into the world without both parents raising them.' When Cooprider reiterated his desire for Davis to 'get rid of it' after her pregnancy test came back positive days later, she asked him to use a different phrase. 'Every time you say 'get rid of it' it's like an electric shock,' she wrote, according to the lawsuit. 'I literally feel like I'm going down the steepest hill on a roller coaster when I read that.' The following text messages allegedly show Cooprider telling Davis, without her approval, that he would order abortion pills online. The pills were purchased from Aid Access, an online service that ships abortion pills to Americans from abroad, according to the lawsuit. Aid Access, and Dr. Rebecca Gomperts, a Dutch physician who runs it, are also listed as defendants in the lawsuit. They did not immediately return requests for comment. For the next several weeks, Cooprider was unable to convince Davis to get an abortion, and the text messages grew more contentious. On March 6, Cooprider called the baby a 'thing' and blamed Davis for her 'psycho mentality' that he said caused her ongoing divorce. The lawsuit says Cooprider also threatened to testify against Davis in her divorce proceeding and bid to have custody of her three children. At the end of March, Cooprider texted that he wanted to 'abort this monstrosity of a situation' and said he felt 'trapped' by the situation. But on April 2, Cooprider appeared to change his tone in text messages to Davis. He proposed making them 'some warm relaxing tea' in what they could call a 'trust building night,' according to screenshots shared in the lawsuit. Davis, who was eight weeks pregnant, accepted. When the two met up at Davis' Corpus Christi residence on the night of April 5, Cooprider handed her a cup of hot chocolate shortly before midnight, according to the lawsuit. Within 30 minutes of drinking it, the suit says, Davis began hemorrhaging and cramping. Davis knew she had to go to the emergency room, but she knew she could not leave her three children who were sleeping upstairs, the suit said. They came up with a plan for Cooprider to pick up Davis' mother, who lived nearby, so she could watch the children while Cooprider took Davis to the hospital. But once Cooprider left the house, he became unreachable, according to the lawsuit. 'I am gushing blood. Please hurry,' Davis texted him around 12:30 a.m. Davis's mother took an Uber ride to her daughter's house around 1 a.m. Around that time, Cooprider apologized and said he had to catch a flight the next day, the suit said. A neighbor drove Davis to the hospital, where her unborn baby, whom she had named Joy, did not survive. Back home, Davis said she found the opened box of abortion pills and a pill bottle, which she turned over to the Corpus Christi police, according to the lawsuit. The suit claims Cooprider mixed 10 misoprostol pills into the hot chocolate. The Corpus Christi Police Department said there are no active investigations involving Cooprider.

Mass. woman raises money on GoFundMe after bat flies into her mouth, prompting $21K medical bill
Mass. woman raises money on GoFundMe after bat flies into her mouth, prompting $21K medical bill

Yahoo

timean hour ago

  • Yahoo

Mass. woman raises money on GoFundMe after bat flies into her mouth, prompting $21K medical bill

A Massachusetts woman who recently lost her job and was left with a $21,000 medical bill after a bat flew into her mouth during a trip to Arizona has set up a GoFundMe to support herself. Westford resident Erica Kahn previously worked as a biomedical engineer, she wrote in her fundraiser campaign's description. She lost her job last summer and thought she would have a new job in a few months. Kahn signed up for new coverage, but she did not know it had a 30-day waiting period, WCVB-TV reported. 'Since I was fun-employed, I traveled to Horseshoe Bend in Arizona, where my dad and I took some long exposure photos of the beautiful landscape at night,' Kahn wrote on GoFundMe. While she was taking photos, she saw bats flying nearby, The Arizona Republic reported. One flew into her mouth. 'As I was screaming, part of the bat unfortunately went in my mouth (fun fact, they taste earthy and a little sweet!),' Kahn wrote on GoFundMe. Kahn's father, who works as a doctor, told her to go to the emergency room for rabies shots, she wrote. Kahn had lost her $650-per-month COBRA plan 11 days earlier. So while she was in the emergency room, she tried to sign up through Innovative Partners Her claims were denied and she received her three shots and four rabies vaccine doses from other hospitals, Kahn wrote. The medical bills totaled $20,749.29. 'It's mentally pretty stressful to think about that sum of money,' Kahn told Republic. Kahn set up the GoFundMe with a goal of donating half of the proceeds to the United Nations Children's Fund (UNICEF) to 'help provide healthcare to families in need,' she wrote. Her goal is to receive $12,000. 'I wish our healthcare system wasn't so broken in the United States,' she continued. 'I believe life-saving medical care is a fundamental human right and it's depressing that Americans can only turn to GoFundMe instead of a federally protected safety net. I made a mistake by choosing not to pay for COBRA, but the cost of these seven shots is pretty extreme. Also, I still believe that bats are an important part of our ecosystem and I feel no ill will toward them! Protect the bats!' The campaign has received 29 donations, including eight $50 donations. 'As Michael Scott said in 'The Office,' 'Myth: three Americans every year die from rabies. Fact: four Americans every year die from rabies,'' Kahn wrote at the end of her campaign. More health-related stories Mass. beach closures: These are the beaches closed on Tuesday, Aug. 5 Worcester health and human services commissioner to retire after 10 years Mass. beach closures: Almost 40 beaches closed on Monday, Aug. 4 Read the original article on MassLive. Solve the daily Crossword

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression

Yahoo

time3 hours ago

  • Yahoo

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression

This designation expands the addressable population for NRX-100 to the 13 million Americans who consider suicide each year and represents a 10x expansion of the addressable population compared to the Designation granted in 2017 for bipolar depression alone The Designation includes an FDA determination that NRX-100 has the potential to address an unmet need, based on FDA's assessment of the data submitted Determination of "unmet need" is a requirement for a Commissioner's National Priority Voucher (CNPV) program. Suicide is a public health crisis. Approximately 13 million adults seriously consider suicide each year, according to the CDC, 3.7 million make a plan to commit suicide. An American dies from suicide every 11 minutes. Active-duty personnel, veterans, and first responders have a four-fold higher risk of suicide. WILMINGTON, Del., Aug. 11, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, today announced US Food and Drug Administration (FDA) has granted Fast Track designation to NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression. This designation for NRX-100 as a standalone drug is a 10-fold expansion of the addressable population for NRX-100, compared to the designation granted in 2017 for NRX-100 in combination with NRX-101 (DCS/lurasidone) for treatment of Suicidal Bipolar Depression. In granting the Fast Track designation, FDA made the determination that NRX-100 has the potential to address an unmet medical need, based on an assessment of the preliminary data contained in the Fast Track designation request. This determination of unmet medical need aligns with the eligibility requirements for the Commissioner's National Priority Voucher Program (CNPV)i and for the FDA's Accelerated Approval The Company has applied for a CNPV, which has the potential to substantially shorten the review cycle for NRX-100. Several well-controlled trials submitted to FDA in support of Fast Track Designation demonstrated a clinically meaningful and statistically significant reduction of suicidal ideation. In a Columbia University study licensed by NRx, suicidal patients treated with intravenous ketamine demonstrated a 55% response (i.e. 50% reduction in suicidality) compared to a 30% response to active comparator (P<.02).iii In a trial sponsored by the Government of France and licensed by NRx, 63% of patients achieved full remission from suicidal ideation in three days compared to 31% of those who received placebo (P<.001). This effect has not been proven with intranasal administration of "We thank FDA for its thoughtful review of our Fast Track designation request, and believe this regulatory determination is a significant step forward in our goal to address the national crisis of suicide among soldiers, first responders, veterans, and civilians alike." said Dr. Jonathan Javitt, Chairman and CEO of NRx Pharmaceuticals. "Large-scale government-supported trials have demonstrated a robust and statistically significant reduction in suicidal ideation and depression with administration of ketamine. This drug was also proven to be non-inferior to electroshock therapy in treating depression without the negative side effects of ECT. We look forward to working closely with the FDA in our quest to Bring Hope to Life." Under the terms of the Fast Track program, NRx will be posting an expanded access policy for NRX-100 in the next two weeks and seeking a meeting with FDA leadership to finalize the data to be submitted under the Accelerated Approval / CNPV application. In addition to the benefits above, Fast Track Designation also grants enhanced communication with the FDA, as well as potential Priority Review and Rolling Review. NRX-100 in Suicidal Ideation in Patients with Depression, Including Bipolar Depression According to the CDC, approximately 13 million adults seriously consider suicide each year, 1.5 million attempt suicide, and an American dies from suicide every 11 minutes. NRX-100 – IV ketamine for suicidality in patients with depression, including bipolar depression – is designed to help address this national crisis. NRx will be submitting patient-level data from controlled clinical trials that demonstrate ketamine to be superior to both a placebo and an active comparator, as well as either non-inferior or superior to electroshock therapy in treating various forms of depression, including patients with active suicidal ideation. Although ketamine in various forms is increasingly used to treat depression and related disorders, it is currently only approved by FDA only for use as an anesthetic and, therefore, not reimbursed by most insurance carriers for treatment of suicidality or depression. Intravenous ketamine is reimbursed by the Department of Veterans Affairs and the Department of Defense for its beneficiaries. By applying for FDA labeling for NRX-100 to treat suicidal depression, the Company hopes to make this potentially life-saving therapy available to all Americans, not just those who are able to pay out of pocket. The Company has previously filed full Chemical Manufacturing and Controls (CMC) information for NRX-100 with FDA and has reported stability and sterility data sufficient to anticipate three-year room temperature shelf life for preservative-free ketamine. Having completed this Fast Track Designation, NRx is now filing draft labeling for NRX-100 to comply with the CNPV requirement. NRX-100 is the first preservative-free presentation of ketamine to be filed with FDA. Currently available product, primarily of foreign manufacture, contains a known toxic preservative, Benzethonium Chloride (BZT) that is not Generally Recognized as Safe (GRAS) and is not allowed by FDA to be used in hand cleaners and topical antiseptics. NRx demonstrated long term stability and sterility with its patented preservative-free formulation of NRX-100. The Company has additionally filed a Citizen Petition seeking to have BZT removed from all intravenous ketamine products. The Company has instituted US-based high-volume manufacture of sterile, preservative-free ketamine. Regarding Fast Track designation, FDA's website states: A drug that receives Fast Track designation is eligible for some or all of the following: More frequent meetings with FDA to discuss the drug's development plan and ensure collection of appropriate data needed to support drug approval. More frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met. Rolling Review, which means that a drug company can submit completed sections of its Biologic License Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA. NRX-100 is poised to address the >$3 billion Suicidal Depression market in the US. References i Grunebaum, et al. Ketamine for rapid reduction of suicidal thoughts… Am J Psychiatry 2018;175: Abbar, et al. Ketamine for the acute treatment of severe suicidal ideation… BMJ 2021;167:194-203 About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner's National Priority Voucher Program for the treatment of suicidal depression. The filing is based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and the Government of France, licensed under a data sharing agreement. Notice Regarding Forward-Looking StatementsThe information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information: Matthew Duffy Chief Business Officer, NRx Pharmaceuticals mduffy@ Brian Korb Managing Partner (917) 653-5122 View original content to download multimedia: SOURCE NRx Pharmaceuticals, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store